Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ANTA PHAR       

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Anthera Pharmaceuticals Inc : Faruqi & Faruqi, LLP is Investigating Anthera Pharmaceuticals Incorporated on Behalf of its Shareholders - ANTH

02/13/2013 | 08:05am US/Eastern

NEW YORK, Feb. 13, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the board of directors of Anthera Pharmaceuticals Incorporated ("Anthera" or the "Company") (Nasdaq: ANTH) concerning possible breaches of fiduciary duty and other violations of law related to the Company's compensation packages for its executive officers. The investigation focuses on the approval and awarding of certain stock options to executives that may have violated the Company's compensation plans.

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

Request more information now by clicking here: www.faruqilaw.com/ANTH

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation. The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you hold ANTH shares and you would like to discuss your legal rights, visit www.faruqilaw.com/ANTH. You can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to mhynes@faruqilaw.com.

Contact:

Faruqi & Faruqi, LLP
Michael J. Hynes, Esq.
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Telephone: (877) 247-4292 or (215) 277-5770
E-mail: mhynes@faruqilaw.com

(Nasdaq: ANTH)

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

React to this article
Latest news on ANTA PHAR
01/28 ANTHERA PHARMACEUTICALS : Entry into a Material Definitive Agreement, Financial ..
01/18 Anthera Pharmaceuticals Appoints Klara Dickinson as SVP, Chief Regulatory Off..
01/13 Anthera Pharmaceuticals Names Klara Dickinson as SVP, Chief Regulatory Office..
01/08 ANTHERA PHARMACEUTICALS : Announces Lupus Symposium During 2015 JP Morgan Health..
01/07 ANTHERA PHARMACEUTICALS : Nasdaq stocks posting largest volume increases
01/07 ANTHERA PHARMACEUTICALS : Change in Directors or Principal Officers, Financial S..
01/07 ANTHERA PHARMACEUTICALS : Announces Appointment of Klara A. Dickinson as Senior ..
01/05 ANTHERA PHARMACEUTICALS : Nasdaq stocks posting largest volume increases
2014 ANTHERA PHARMACEUTICALS : Announces Lupus Symposium During 2015 JP Morgan Health..
2014 ANTHERA PHARMACEUTICALS : Termination of a Material Definitive Agreement (form 8..
Dynamic quotes  
ON
| OFF